ReviewExpert opinion on biological therapy2018
Repairing the corneal epithelium using limbal stem cells or alternative cell-based therapies.
Review in Expert opinion on biological therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Preclinical Models of Rare Corneal and Ocular Surface Diseases: a Comprehensive Narrative Review.Ophthalmology and therapy · 2026Review
- Limbal stem cell sheet bandage for short-term treatment of corneal regeneration.BMC ophthalmology · 2025Article
- Bio-orthogonal crosslinking and hyaluronan facilitate transparent healing after treatment of deep corneal injuries with in situ-forming hydrogels.NPJ Regenerative medicine · 2025Article
- Understanding the cellular dynamics, engineering perspectives and translation prospects in bioprinting epithelial tissues.Bioactive materials · 2025Review
- Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art.Biotech (Basel (Switzerland)) · 2023Review
- MLN4924 Promotes Self-Renewal of Limbal Stem Cells and Ocular Surface Restoration.Journal of personalized medicine · 2023Article
- Current and Emerging Therapies for Limbal Stem Cell Deficiency.Stem cells translational medicine · 2022Article
- Regenerative therapy for the Cornea.Progress in retinal and eye research · 2022Review
- Corneal epithelial differentiation of human pluripotent stem cells generates ABCB5Stem cell research & therapy · 2021Article
- Human iPS cells engender corneal epithelial stem cells with holoclone-forming capabilities.iScience · 2021Article
- Process development and safety evaluation of ABCB5Stem cell research & therapy · 2021Article
- Peripheral Blood As a Source of Stem Cells for Regenerative Medicine: Emphasis Towards Corneal Epithelial Reconstruction-An In Vitro Study.Tissue engineering and regenerative medicine · 2020Article
- Article
- Investigation of factors associated with ABCB5-positive limbal stem cell isolation yields from human donors.The ocular surface · 2020Article
- Corneal Stem Cells as a Source of Regenerative Cell-Based Therapy.Stem cells international · 2020Review
- The Ocular Neural Crest: Specification, Migration, and Then What?Frontiers in cell and developmental biology · 2020Review
- Understanding cornea homeostasis and wound healing using a novel model of stem cell deficiency in Xenopus.Experimental eye research · 2019Article
- Recovering vision in corneal epithelial stem cell deficient eyes.Contact lens & anterior eye : the journal of the British Contact Lens Association · 2019Review
- Corneal Repair and Regeneration: Current Concepts and Future Directions.Frontiers in bioengineering and biotechnology · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
introductionThe corneal epithelium is maintained by limbal stem cells (LSCs) that reside in the basal epithelial layer of the tissue surrounding the cornea termed the limbus. Loss of LSCs results in limbal stem cell deficiency (LSCD) that can cause severe visual impairment. Patients with partial LSCD may respond to conservative therapies designed to rehabilitate the remaining LSCs. However, if these conservative approaches fail or, if complete loss of LSCs occurs, transplantation of LSCs or their alternatives is the only option. While a number of clinical studies utilizing diverse surgical and cell culture techniques have shown favorable results, a universal cure for LSCD is still not available. Knowledge of the potential risks and benefits of current approaches, and development of new technologies, is essential for further improvement of LSCD therapies. AREAS COVERED: This review focuses on cell-based LSCD treatment approaches ranging from current available clinical therapies to preclinical studies of novel promising applications. EXPERT OPINION: Improved understanding of LSC identity and development of LSC expansion methods will influence the evolution of successful LSCD therapies. Ultimately, future controlled clinical studies enabling direct comparison of the diverse employed approaches will help to identify the most effective treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.